Introduction {#s1}
============

Copy number variants are insertions, deletions or duplications of segments of DNA. They can be found in healthy individuals, or be associated with disease. They have been the focus of considerable recent interest in neurological disorders [@pone.0034813-Conrad1], [@pone.0034813-Shaikh1]. In particular, 16p13.11 copy number changes are associated with schizophrenia [@pone.0034813-Need1], mental retardation [@pone.0034813-Hannes1], [@pone.0034813-Ullmann1], attention-deficit hyperactivity disorder [@pone.0034813-Williams1] and both idiopathic generalised [@pone.0034813-deKovel1]--[@pone.0034813-Mefford1] and focal epilepsies [@pone.0034813-Heinzen1]. In our previous study, we found 23/3812 patients had \>100 kb deletions at 16p13.11, with Nuclear Distribution gene E homolog 1 (*NDE1*) involved in 22/23 [@pone.0034813-Heinzen1]. *NDE1* encodes a protein that belongs to the highly-conserved nuclear distribution protein family. The Nde1 protein predominantly interacts both with Lissencephaly-1 (Lis-1), a protein essential for lamination of the cerebral cortex [@pone.0034813-Feng1]--[@pone.0034813-Pawlisz1], and with dynein, a cytoplasmic motor protein that directs cellular cargos towards the 'minus end' of microtubules [@pone.0034813-Feng1], [@pone.0034813-Lam1]--[@pone.0034813-Vergnolle1]. Together, the Nde1-Lis-1-dynein complex mediates a range of intracellular motility activities, including the transport of organelles to the centrosomes, the orientation of mitotic spindles, the separation of chromosomes during mitosis and the assembly of centrosomes and spindles [@pone.0034813-Pawlisz1], [@pone.0034813-Vergnolle1]--[@pone.0034813-Sasaki2], all of which are important for cortical development.

*NDE1* loss has been suggested a prime candidate for disease mechanisms associated with 16p13.11 deletion [@pone.0034813-Hannes1], [@pone.0034813-Ramalingam1]. Deficiency of Lis-1 and Nde1 expression in *Lis-1* and *Nde1* mutant mice and *Nde1* knockout mice results in a marked loss of cortical lamination, reduced brain size and a reduction in precursor cell division and segregation [@pone.0034813-Feng1]--[@pone.0034813-Pawlisz1], [@pone.0034813-Sasaki2]. In humans, *LIS1* haploinsufficiency (from a deletion at 17p13.3) results in Type 1 Lissencephaly or Miller Dieker syndrome, where patients have gross cortical dyslamination, a resulting smooth or under-folded cortex, and may experience epileptic seizures [@pone.0034813-Dobyns1], [@pone.0034813-LoNigro1]. Similarly, patients with homozygous frameshift mutation in *NDE1* show microlissencephaly (reduced brain size and simplified cortex) and experience seizures starting early in life [@pone.0034813-Alkuraya1], [@pone.0034813-Bakircioglu1]. Heterozygous deletion of *NDE1* specifically may be a prime cause of epilepsy, both focal and idiopathic generalised, associated with 16p13.11 deletion [@pone.0034813-deKovel1], [@pone.0034813-Heinzen1], [@pone.0034813-Nagamani1]. Testing of this hypothesis directly in humans is difficult as the deletion is rare, and brain tissue is almost never available from patients with idiopathic generalised epilepsies. In our cohort of patients with focal epilepsy however, there were two patients with mesial temporal lobe epilepsy (MTLE) with *NDE1*-containing 16p13.11 deletion, who had previously undergone temporal lobectomy as treatment for their drug-resistant seizures. This surgically-resected material allows direct examination in the target tissue of the consequences of heterozygous *NDE1* deletion. We tested the hypothesis that *NDE1* loss would cause cortical dyslamination, using immunohistochemistry for a range of layer-specific, neural precursor and migratory cell markers.

Results {#s2}
=======

The disease cases 1 and 2 both had the same 800 kb 16p13.11 deletion including *NDE1*.

Histological staining {#s2a}
---------------------

The temporal cortex of Case 1, Case 2 and disease controls appeared normal with no cell loss or dyslamination evident in H+E, LFB or anti- Neuronal Nuclei (NeuN) labelled sections ([Figure 1](#pone-0034813-g001){ref-type="fig"}). LFB and Alcian Blue stains revealed a well-defined nodule of 3 mm in diameter, with an accumulation of metachromatic material, in the subcortical white matter of the middle temporal gyrus of Case 1 ([Figure 2A--B](#pone-0034813-g002){ref-type="fig"}). This nodule was composed of small, round cells that were immunopositive for microtubule-associated protein 2 (MAP2; [Figure 2C--D](#pone-0034813-g002){ref-type="fig"}) but not immunopositive for glial fibrillary acidic protein (GFAP), NeuN, synaptophysin or neurofilaments. These MAP2-immunopositive cells intermingled with larger, NeuN-immunopositive neurons and GFAP-immunopositive reactive astrocytes inside the nodule. Together, these neuropathological findings define the nodule as a hamartia (a small hamartoma [@pone.0034813-Scaravilli1], [@pone.0034813-Wolf1]). The overlying cortex appeared normal and serial sections taken from either side showed that the hamartia was neither part of a glio-neuronal tumour nor part of a larger malformation. Case 2 and other disease controls did not show pathological features indicative of a hamartia.

![The temporal cortex of Case 2.\
The cortical lamination of the temporal cortex of Case 2 was normal, as compared to the MTLE case without *NDE1* deletion and non-epilepsy surgical controls. Scale = 200 µm.](pone.0034813.g001){#pone-0034813-g001}

![Hamartia in the temporal cortex of Case 1.\
LFB (A) and Alcian Blue (B) stains showed the location of the hamartia within the middle temporal gyrus (\*). Small, round cells inside the hamartia were immunopositive for MAP2 as viewed at a low (C) and high (D) magnification. Scale = 100 µm (A--C), 20 µm (D).](pone.0034813.g002){#pone-0034813-g002}

The hippocampus of Case 1 was normal, with no loss of cells in H+E, LFB and anti-NeuN labelled sections. Pre-operative magnetic resonance imaging (MRI) showed that Case 2 had a smaller left hippocampus compared to the right ([Figure 3A](#pone-0034813-g003){ref-type="fig"}). Microscopic examination of Case 2\'s surgically-resected left hippocampus revealed a marked loss of NeuN-immunopositive neurons in the cornu Ammonis (CA) 4, 3 and 1 ([Figure 3B](#pone-0034813-g003){ref-type="fig"}). The loss of NeuN-immunopositive cells in CA regions was also noted in the MTLE control without *NDE1* deletion ([Figure 3C](#pone-0034813-g003){ref-type="fig"}). Granule cell dispersion was present in Case 2. A dense matrix of GFAP-immunopositive cells and processes was observed throughout the hippocampus of Case 2, particularly in CA regions ([Figure 3D](#pone-0034813-g003){ref-type="fig"}). Dynorphin ([Figure 3E](#pone-0034813-g003){ref-type="fig"}) and neuropeptide Y immunoreactivities were evident in the inner, middle and outer molecular layers of the dentate gyrus of Case 2, confirming mossy fibre spouting. Together, these features were consistent with hippocampal sclerosis, a common pathology observed in MTLE [@pone.0034813-Thom1].

![Hippocampal sclerosis in Case 2.\
(A) A coronal MRI image of Case 2 showing left hippocampal atrophy (\*; inset). No cerebral malformations were evident. The histology showed hippocampal sclerosis: (B) NeuN-immunopositive cells were lost in the cornu Ammonis (CA) regions of the left hippocampus of Case 2, as seen in the MTLE control case without *NDE1* deletion (C). (D) Strong GFAP-immunoreactivity was observed in all regions of the hippocampus of Case 2. (E) Dynorphin-immunoreactivity was observed throughout the molecular layer of Case 2, demonstrating the presence of mossy fibre spouting. GCL = granule cell layer, MOL = molecular cell layer. Scale = 100 µm (B--E).](pone.0034813.g003){#pone-0034813-g003}

Layer-specific markers {#s2b}
----------------------

We examined the lamination of the temporal cortex and anatomy of the hippocampus of Case 1, Case 2 ([Figure 4A](#pone-0034813-g004){ref-type="fig"}, [Figure S1A](#pone.0034813.s001){ref-type="supplementary-material"}) and disease controls ([Figure 4B](#pone-0034813-g004){ref-type="fig"}, [Figure S1B](#pone.0034813.s001){ref-type="supplementary-material"}) using layer-specific immunohistochemical markers: anti-microtubule-associated protein 1B (MAP1B), N200, SMI32, anti-calretinin, anti-calbindin and anti-parvalbumin. These layer-specific markers label cell types specifically distributed within certain human cortical layers [@pone.0034813-Ferrer1]--[@pone.0034813-Thom2]. The white matter of Case 1, Case 2 and disease controls was investigated using SMI94 and anti-nogo-A antibodies. Nogo-A is a reticulin family protein expressed mostly by oligodendrocytes in the brain [@pone.0034813-Bandtlow1].

![MAP1B, SMI32, Calbindin and SMI94-immunopositive labelling in the temporal cortex of Case 2 and the MTLE control.\
MAP1B and calbindin-immunopositive cells were predominantly observed in the upper cortical layers, while SMI32-immunopositive cells and processes were mainly found in the lower cortical layers of MTLE cases with (A) or without *NDE1* deletion (B). Immunoreactivity of SMI94 was observed in the lower cortical layers and white matter of both cases. Scale = 200 µm (A, B).](pone.0034813.g004){#pone-0034813-g004}

The pattern of immunolabelling with layer-specific and white matter markers was similar for Case 1, Case 2 and disease controls. In the temporal cortex, many MAP1B-, N200-, SMI32-, calretinin-, calbindin-, parvalbumin-immunopositive cells were observed in the upper cortical layers (II and III) of Case 1, Case 2 ([Figure 4A](#pone-0034813-g004){ref-type="fig"}, [Figure S1A](#pone.0034813.s001){ref-type="supplementary-material"}) and disease controls ([Figure 4B](#pone-0034813-g004){ref-type="fig"}, [Figure S1B](#pone.0034813.s001){ref-type="supplementary-material"}). A few MAP1B-, N200-, SMI32-, calbindin- and parvalbumin- immunopositive cells were also observed in the lower cortical layers (IV, V and/or VI) of all cases. All immunopositive cells in Case 1 and 2 appeared normal with no atypical or dysplastic features. Thick, SMI94-immunopositive radial fibres were predominantly observed from cortical layer IV to the white matter of all cases, with fewer horizontal fibres highlighted in layer I of Case 1, Case 2 ([Figure 4A](#pone-0034813-g004){ref-type="fig"}) and disease controls ([Figure 4B](#pone-0034813-g004){ref-type="fig"}). In the white matter of all cases, nogo-A-immunopositive cells were small and round, with labelling restricted to the scant cell body of oligodendrocytes. Nogo-A-immunopositive cells were found predominantly in the white matter rather than the gray matter.

In the hippocampus of all cases, MAP1B-, N200-, SMI32- calretinin-, calbindin- and parvalbumin-immunopositive cells were observed in the CA regions and subiculum. There were visibly fewer N200-, SMI32-, calretinin-, calbindin- and parvalbumin-immunopositive cells in the CA regions of Case 2 and the MTLE control without *NDE1* deletion, than in Case 1 and non-epilepsy controls, in keeping with the presence of hippocampal sclerosis in the MTLE disease control and Case 2. MAP1B- and calbindin-immunopositive granule cells were evident in the granule cell layer of all cases. Parvalbumin-immunopositive processes or synapses were often observed between granule cells in the GCL and the CA2 region of all cases ([Figure 5](#pone-0034813-g005){ref-type="fig"}). Nogo-A-immunopositive oligodendrocytes were evident in the white matter of all cases.

![Parvalbumin-immunopositive labelling in the hippocampus of Case 2.\
A few numbers of parvalbumin-immunopositive cells were still observed in CA4 (A) and CA2 (B) of the sclerotic hippocampus of Case 2. Some parvalbumin-immunopositive processes and plexuses were observed around granule cells (A) and surviving pyramidal neurons in CA2 (B). CA = cornu Ammonis, GCL = granule cell layer. Scale = 20 µm (A, B).](pone.0034813.g005){#pone-0034813-g005}

Precursor and migratory cell markers {#s2c}
------------------------------------

Antibodies against nestin, GFAPδand PAX6 label neural precursor cells [@pone.0034813-Blumcke1]--[@pone.0034813-Roelofs1], while antibodies against DCX and reelin label migratory cells in the developing and adult mammalian brain [@pone.0034813-Gleeson1]--[@pone.0034813-Gong1]. The immunolabelling of these markers was not markedly different between Case 1, Case 2 and disease controls.

Nestin-, GFAPδ-, PAX6-, DCX- and reelin-immunopositive cells were predominantly observed in cortical layer I and white matter of Case 1, Case 2 ([Figure 6A--C](#pone-0034813-g006){ref-type="fig"}, [7A--B](#pone-0034813-g007){ref-type="fig"}) and disease controls. GFAPδ- and DCX-immunopositive cells were binucleated or multinucleated with glial-like processes. Nestin-immunopositive blood vessels were observed throughout the cortex. A few GFAPδ-immunopositive cells were observed in the deeper cortex and in the white matter of all cases; they were often situated around blood vessels. PAX6- and small, reelin-immunopositive cells could also be seen in the other cortical layers of all cases.

![Nestin, GFAPδ and PAX6 immunopositive labelling in the temporal cortex and hippocampus of Case 2.\
Nestin- (A) and GFAPδ (B) strongly immunopositive glial-like cells were observed in cortical layer I and white matter of the temporal cortex and the hippocampus of Case 2. Nestin-immunopositive cells with short, unipolar processes were occasionally found in the white matter of Case 2 (A, middle inset). Small, round PAX6-immunopositive cells were found throughout the temporal cortex and hippocampus. BV = blood vessels, CA = cornu Ammonis, GCL = granule cell layer. Scale = 20 µm (A--C), 10 µm (A, middle inset).](pone.0034813.g006){#pone-0034813-g006}

![DCX and reelin-immunopositive labelling in the temporal cortex of Case 2.\
In cortical layer I, DCX-immunopositive cells with a glial-like morphology clustered in groups of two or three (arrows, A). DCX-immunopositive cells with short, bipolar processes were occasionally observed in the upper cortical layers (A inset). Reelin-immunopositive cells were also observed in cortical layer I (B) and in deeper cortical layers of Case 2 (B, inset). Scale = 10 µm (A, B, insets).](pone.0034813.g007){#pone-0034813-g007}

In the hippocampus, GFAPδ-immunopositive cells were observed in all CA regions, particularly in the sclerotic hippocampus of Case 2 and the MTLE control case without *NDE1* deletion. PAX6- and DCX-immunopositive cells were observed throughout the hippocampus, particularly in the CA4 and granule cell layer of all cases. Large, reelin-immunopositive cells were observed in the CA4 region and in the molecular layer of the dentate gyrus, while small reelin-immunopositive cells were observed throughout the hippocampus.

NDE1 {#s2d}
----

The immunoreactivity of NDE1 was observed in the cytoplasm of neurons throughout the temporal cortex and hippocampus of Case1 and 2 and disease controls ([Figure 8](#pone-0034813-g008){ref-type="fig"}). No marked difference in immunolabelling was observed between Case 1, Case 2 and disease controls.

![NDE1-immunopositive labelling in the temporal cortex of Case 2 and MTLE case without *NDE1* deletion.\
The immunoreactivity of NDE1 (arrows) was predominantly observed in the cytoplasm of neurons in Case 2 and the epilepsy control.](pone.0034813.g008){#pone-0034813-g008}

Multidrug resistance-related protein 1 {#s2e}
--------------------------------------

The chromosomal region 16p13.11 also contains *ABCC1*, which encodes the multidrug resistance-related protein 1 (MRP1). We investigated MRP1 expression using MRPr1, an antibody which has been used in previous human studies [@pone.0034813-Sisodiya1], [@pone.0034813-Liu1]. MRPr1-immunopositive blood vessels were observed throughout temporal cortex and hippocampus of Case 1, Case 2 ([Figure 9A--B](#pone-0034813-g009){ref-type="fig"}) and disease controls. Many MRPr1- immunopositive glial cells and fibres were also observed in the cortical layer I and white matter of the temporal cortex and the hippocampal CA regions. Most MRPr1-immunopositive glial cells were found around blood vessels ([Figure 9B](#pone-0034813-g009){ref-type="fig"}). The glial expression of anti-MRP1 has been previously described in studies using surgical MTLE tissue without known *NDE1* deletion [@pone.0034813-Sisodiya1]. Disease controls showed a similar pattern of MRP1 immunoreactivity to that seen in Case 1 and Case 2.

![MRP1-immunopositive labelling in the temporal cortex and hippocampus of Case 2.\
(A) Many MRP1-immunopositive cells and processes were observed in the hippocampus. (B) MRP1-immunopositive cells were also evident in the temporal cortex (usually around blood vessels). CA = cornu Ammonis, GCL = granule cell layer, BV = blood vessel. Scale = 50 µm (A), 20 µm (B).](pone.0034813.g009){#pone-0034813-g009}

Discussion {#s3}
==========

Two key challenges in disease genetics are to identify pathogenic genetic changes and to understand how these changes lead to disease phenotypes. For neuropsychiatric diseases, the latter challenge is often especially daunting, as direct study of the organ involved, the brain, is usually impossible. But such studies, using brain material from patients with the neurological disease in question, especially those with known genetic abnormalities, are important as they may provide valuable insights and bounds about the effects of genetic variants on brain structure and disease mechanisms. We examined the surgically-resected temporal cortex and hippocampus of two people with MTLE with identical 800 kb deletion at 16p13.11, encompassing seven genes, including *NDE1* and *ABCC1*. In Case 1, the white matter of the temporal cortex contained a hamartia, which was not associated with any overlying cortical dyslamination or any dysmorphic neurons, balloon cells or more extensive changes seen in glio-neuronal tumours. In Case 2, we found neuronal cell loss, gliosis and re-organisation, changes typical of hippocampal sclerosis. The genetic basis, if any, of hippocampal sclerosis is unknown: in our previous study [@pone.0034813-Heinzen1], only 2/23 patients with 16p13.11 deletions had hippocampal sclerosis, whilst other microdeletions are also associated with hippocampal sclerosis [@pone.0034813-Catarino1]. Both hamartia and hippocampal sclerosis occur in patients with drug-resistant epilepsy [@pone.0034813-Wolf1], [@pone.0034813-Thom3], and are unlikely to be due to the 16p13.11 deletion.

Case 1 and Case 2 both had a normal, hexalaminar temporal cortex, housing appropriate layer-specific cell types. No marked difference was observed for NDE1 immunoreactivity or expression of proteins associated with cell division and migration in the temporal cortex or hippocampus of either case in comparison to disease controls. NDE1 immunoreactivity in both Case 1 and 2 and disease controls was localised to the cytoplasm of neurons, which is consistent with its role in intracellular transport [@pone.0034813-Sasaki2], [@pone.0034813-Shmueli1].

In animal studies, *Nde−/−* mutants have no *Nde1* expression and possess a brain that is a third smaller than controls, while heterozygous *Nde1+/−* mutant mice express a considerable amount of NDE1 protein, that is only slightly lower than controls in immunoblotting experiments, and these heterozygous *Nde1 +/−* mutant mice have brain size and weight comparable to controls [@pone.0034813-Feng2]. Humans with 1 to 3.4 Mb homozygous deletions at 16p13.11 have small stature, dysmorphic features, seizures, microcephaly or microlissencephaly [@pone.0034813-Hannes1], [@pone.0034813-Alkuraya1]. In humans, the contrasting phenotypes of duplication and deletion suggest 16p13.11 is a dosage-sensitive region [@pone.0034813-Nagamani1]. However, the resected brain tissue of our two patients with heterozygous 16p13.11 deletion was normal for the parameters we examined. Moreover, these patients did not have intellectual disability, or any remarkable abnormalities of appearance or stature. Therefore, no clear dose-dependency phenomenon is apparent in our two patients with, at least, loss of one copy of the whole *NDE1* gene. If 16p13.11 deletion contributes to brain disease in our two patients through loss of at least one copy of *NDE1*, as is the current favoured hypothesis, then this contribution to disease would not seem to be through pathology obvious at the light microscopic level or immunophenotypically-determined dyslamination. The deletion of *NDE1* could act at another, for example submicroscopic, level; it is also possible that the deletion unmasks a recessive mutation on the remaining allele, but this is unlikely given the normal appearance and cognitive abilities of our two patients and previous examination of this possibility [@pone.0034813-Heinzen1]. Alternatively, loss of NDE1 in patients with heterozygous *NDE1* deletion may possibly be compensated by other proteins with similar functions such as LIS1 or NDE1-related protein 1 (NDEL1), a homolog of NDE1 [@pone.0034813-Lam1], [@pone.0034813-Sasaki1], [@pone.0034813-Derewenda1].

Finally, it is possible that at least in our two patients, loss of NDE1 is not the key contributor to disease (here, epilepsy) associated with 16p13.11 deletion, suggesting that other candidates and mechanisms need to be sought. Overall, however, the link between heterozygous deletion of 16p13.11 and epilepsy, and other neuropsychiatric diseases, is clear [@pone.0034813-Mefford1], [@pone.0034813-Heinzen1]: this deletion is not a polymorphism, and is at the very least a disease risk factor. In Case 1, seizures continued despite surgery, implying that epileptogenic tissue remained unresected. The 16p13.11 deletion in this case may therefore have conceivably acted as a risk factor for epilepsy by subtly altering brain structure beyond the resected tissue, a possibility we could not test as only resected tissue was available for analysis. We note, however, that *NDE1* is expressed in the human temporal lobe (e.g. [@pone.0034813-Bakircioglu1], such that if *NDE1* deletion were acting by altering microscopic brain structure, examination for such changes in the temporal lobe would be a reasonable strategy: we did not find any alteration with the methods employed.

Our study illustrates the central role for detailed phenotyping in interpretation of genetic findings: for neurogenetics, human neuropathological studies are key, setting boundaries for putative mechanisms of action of identified genetic mutations. We anticipate an increasing role for such studies in human genetic diseases in general.

Materials and Methods {#s4}
=====================

The study was approved by the Joint Research Ethics Committee of the Institute of Neurology and the National Hospital for Neurology and Neurosurgery. The work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki). Written informed consent was obtained for research. We examined surgically-resected temporal cortical and hippocampal tissue from two MTLE patients with confirmed 16p13.11 deletion. Their clinical details and results from genetic analysis are described in [Table 1](#pone-0034813-t001){ref-type="table"} and [Figure 10](#pone-0034813-g010){ref-type="fig"}. Neither of the patients has learning disability. No structural abnormalities were observed in MRI, apart from Case 2 who had a smaller left hippocampus compared to the right. Surgically-resected temporal cortex and hippocampus of a patient with MTLE known not to have the deletion of the entire *NDE1* gene, and resected neocortical tissue from three trauma patients were used as disease controls in immunohistochemical studies ([Table 1](#pone-0034813-t001){ref-type="table"}). The three trauma patients were not tested for the 16p13.11 deletion, but the frequency of this deletion in patients with focal epilepsy was 0.6%, and the deletion was not observed in unselected controls [@pone.0034813-Heinzen1], so it is very unlikely that all these three (or indeed any one) of the disease control patients had the deletion.

![An illustration showing deleted genes in 16p13.11 in Case 1 and Case 2.](pone.0034813.g010){#pone-0034813-g010}

10.1371/journal.pone.0034813.t001

###### Clinical details of cases.

![](pone.0034813.t001){#pone-0034813-t001-1}

  MTLE cases with 16p13.11 deletion                                                                                                                                                                                                                                                                                                                 
  ----------------------------------- ------ ----------------------------------- ---------- ------------------------------------------------------------------- --------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------
  Case 1                               M/36   chr16:15387380-16225138 (837,758)   16p13.11   *MPV17L, C16orf45, NDE1, MYH11, C16orf63, KIAA0430, ABCC1, ABCC6*   Hippocampal and temporal cortical resection   Hamartia in the subcortical white matter of the middle temporal gyrus. Not all hippocampal subfields were available for assessment.   Still experienced frequent seizures
  Case 2                               F/37   chr16:15387380-16225138 (837,758)   16p13.11   *MPV17L, C16orf45, NDE1, MYH11, C16orf63, KIAA0430, ABCC1, ABCC6*   Hippocampal and temporal cortical resection                                      Hippocampal sclerosis (cell loss and gliosis in CA1, 3 and 4)                                          Seizure free after surgery

  Control cases            
  --------------- --- ---- ----------
  N1               F   45   Epilepsy

  Non-epilepsy cases            
  -------------------- --- ---- -----------------------------
  N2                    F   57   Head injury, brain swelling
  N3                    M   41           Head injury

All surgical tissue was fixed, processed and paraffin-embedded within one week following surgery. Routine histology staining, including haematoxylin and eosin (H+E) and luxol fast blue (LFB), was performed. Alcian Blue, an acid-mucosubstance stain, was used in Case 1 to investigate the observed hamartia. Automated immunohistochemistry was performed using Bond Max Automated Immunostainer and reagents (Leica, UK). 5 µm sections on adhesive microscopic slides (Raymond A Lamb, UK) were first processed in dewaxing solution and 100% alcohol. Antigen retrieval protocols were applied as detailed in [Table 2](#pone-0034813-t002){ref-type="table"} before sections were immersed in 3% hydrogen peroxide solution for 5 minutes. Sections were incubated with primary antibodies for 15 minutes. Post-primary polymer solutions were applied for 8 minutes. Chromogen activation was achieved using diaminobenzidine. Sections were dewaxed and rehydrated through xylene and graded alcohols and taken to water. Antigen retrieval procedures were applied as described in [Table 2](#pone-0034813-t002){ref-type="table"}. All sections were outlined using a wax pen before placing flat in an immunohistochemical humidity chamber. Primary antibodies were diluted with Dako diluent and then incubated on sections as detailed in [Table 2](#pone-0034813-t002){ref-type="table"}. NDE1 primary antibody was used at 1∶500. The following day, sections were incubated in Dako Envision horseradish peroxide solution for 30 minutes. Chromogen activation was performed using Dako Envision diaminobenzidine and substrate buffer for 5 minutes. Sections were washed in phosphate buffer solution between each step. Sections with omission of primary antibodies or their replacement non-specific IgG were included in experiments as negative control. Sections were then processed through graded alcohols and xylene and coverslipped (TissueTek). A light microscope and camera (Nikon Eclipse 80i and Sight DS Fi1) were used to visualize sections and to capture images. Montages were acquired using the JVC camera attached to an ImagePro Plus system (Media Cybernetics, USA). The specificity of the antibody against NDE1 was tested (see [Figure S2](#pone.0034813.s002){ref-type="supplementary-material"}).

10.1371/journal.pone.0034813.t002

###### Primary antibodies used in the study.

![](pone.0034813.t002){#pone-0034813-t002-2}

  Antibodies                  Description                       Source               Antibody: concentration and type   Mode of immuno-histochemical staining   Antigen retrieval protocol using Vector\'s unmasking buffer   Condition of Primary antibody incubation
  ------------------ ------------------------------ ------------------------------- ---------------------------------- --------------------------------------- ------------------------------------------------------------- ------------------------------------------
  N200                 Layer specific cell marker             Sigma, USA                    1∶3000 polyclonal                          Manual                                         12 minutes, mw                                         1 hour, RT
  SMI32                Layer specific cell marker            Covance, USA                    1∶500 monoclonal                          Manual                                         12 minutes, mw                                         1 hour, RT
  Anti-MAP1B           Layer specific cell marker              Abcam, UK                    1∶2500 monoclonal                          Manual                                         15 minutes, mw                                       overnight, RT
  Anti-calretinin      Layer specific cell marker             Sigma, USA                    1∶3000 polyclonal                          Manual                                          12 minutes,mw                                       overnight, RT
  Anti-calbindin       Layer specific cell marker          Swant,Switzerland                1∶10000 polyclonal                         Manual                                         12 minutes, mw                                       overnight, RT
  Anti-parvalbumin     Layer specific cell marker         Swant , Switzerland               1∶5000 polyclonal                          Manual                                         12 minutes, mw                                       overnight, RT
  Anti-nestin         Neural precursor cell marker    Chemicon International, USA           1∶8000 polyclonal                         Automated                                       20 minutes, mw                                       15 minutes, RT
  Anti-PAX6           Neural precursor cell marker   Santa Cruz Biotechnology, USA           1∶50 monoclonal                           Manual                                         15 minutes, mw                                       overnight, 4°C
  Anti-GFAPδ             migratory cell marker        Chemicon International, USA           1∶5000 Polyclonal                          Manual                                         12 minutes, mw                                       36 hours, 4°C
  Anti-DCX               migratory cell marker                 Abcam, UK                    1∶4000 polyclonal                          Manual                                         10 minutes, mw                                       overnight, RT
  Anti-reelin            migratory cell marker        Chemicon International, USA           1∶1000 monoclonal                          Manual                                           12 minutes                                         overnight, RT
  SMI94                   white matter marker                Covance, USA                   1∶2000 monoclonal                         Automated                                10 minutes, enzyme treatment                                15 minutes, RT
  Anti-nogo-A           oligodendricytes marker       Chemicon International, USA            1∶500 polyclonal                         Automated                                20 minutes, enzyme treatment                                15 minutes, RT
  Anti-MRP1              ABC transporter marker        Alexis Biotechnology, USA             1∶30 monoclonal                           Manual                               6 minutes, EDTA buffer (Sigma, USA)                            overnight, RT

mw = microwave; RT = room temperature.

Supporting Information {#s5}
======================

###### 

**Immunoreactivities of layer-specific markers in the temporal cortex of Case 2 and the MTLE control.** MAP1B, calretinin, calbindin and parvalbumin-immunopositive cells were predominantly observed in the upper cortical layers, while N200- and SMI32-immunopositive cells and processes were mainly found in the lower cortical layers of MTLE cases with (A) or without *NDE1* deletion (B). Immunoreactivity of SMI94 was observed in the lower cortical layers and white matter of both cases. Scale = 200 µm (A, B).

(PDF)

###### 

Click here for additional data file.

###### 

**The specificity of the antibody against NDE1.** Immunoblotting experiment detected NDE1 at ∼38 kDa, the expected molecular weight of the protein, in the lysate from the resected temporal cortex of patient with mesial temporal lobe epilepsy.

(TIF)

###### 

Click here for additional data file.
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